Search
for
Sort by
Research 31–60 of 330
- Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Alopecia Universalis: Never Give Up?
- What’s new in the treatment of hair loss?
- A superb way to split hairs
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- Survey of pediatric dermatologist views on treatment for alopecia areata
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- 504 A single-center retrospective study evaluating the efficacy of intravenous methylprednisolone pulse therapy for 113 patients with alopecia areata
- New Treatment Options for Alopecia Areata
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- 013 IL-15/IL-15Rα signaling is a guardian of human hair follicle immune privilege and promotes hair growth
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- 77200 Infections and Therapy Lapses Predominate as Flare Triggers on Oral JAK Inhibitors for Alopecia Areata: A Retrospective Cohort Study
- Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Perceived Efficacy and Risks of Janus Kinase Inhibitors in Pediatric and Young Adult Alopecia Areata: A Cross‐Sectional Survey
- BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series